Initial nivolumab-based treatment halts melanoma progression

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Phase III study finds initial nivolumab-based treatment halts melanoma progression

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Ibrutinib combination regimen shows substantial benefits in relapsed CLL

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction